Nevertheless, it is essential that substrate drugs (topotecan, irinotecan, anthracyclines, mitomycin C and trimetrexate) for Pgp and/or BCRPS used clinically in colon cancer be administered in conjunction with chemosensitizers (VX-710 [43], GF120918 [44,45], and XR-9576 [46,47]), which can reverse both Pgp and BCRP. This evidence concerns the gene PGP and malignant colon neoplasm.